XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.22.4

SHAREHOLDERS’ EQUITY | 12 Months Ended
--- | ---
Oct. 31, 2022
Equity [Abstract] |
SHAREHOLDERS’ EQUITY | 5. SHAREHOLDERS’ EQUITY Stock Option Plans During the year ended October 31, 2022, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”) which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS During the year ended October 31, 2022, stock options to purchase 793,103 shares, net of 1,083,517 shares withheld on cashless exercises, were exercised with aggregate proceeds of approximately $439,000. During the year ended October 31, 2021, stock options to purchase 207,697 shares, net of 60,691 shares withheld on cashless exercises, were exercised with aggregate proceeds of approximately $434,000. 2010 Share Plan The 2010 Share Plan provides for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. On the first business day of each calendar year the aggregate number of shares available for future issuance is replenished such that 800,000 shares are available. The exercise price with respect to all of the options granted under the 2010 Share Plan was equal to the fair market value of the underlying common stock at the grant date. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the grant of future options on July 14, 2020. Information regarding the 2010 Share Plan for the two years ended October 31, 2022 is as follows: SCHEDULE OF OPTION ACTIVITY
|  | Shares |  |  | Weighted Average Exercise Price Per Share |  |  | Aggregate Intrinsic Value |
Options Outstanding at October 31, 2020 |  |  | 1,907,534 |  |  | $ | 2.82 |  |  |  |  |
Exercised |  |  | (178,500 | ) |  | $ | 2.75 |  |  |  |  |
Expired |  |  | (10,400 | ) |  | $ | 4.57 |  |  |  |  |
Options Outstanding at October 31, 2021 |  |  | 1,718,634 |  |  | $ | 2.82 |  |  |  |  |
Exercised |  |  | (212,000 | ) |  | $ | 2.68 |  |  |  |  |
Expired |  |  | (5,134 | ) |  | $ | 3.63 |  |  |  |  |
Options Outstanding and Exercisable at October 31, 2022 |  |  | 1,501,500 |  |  | $ | 2.83 |  |  | $ | 4,156,000 |
The following table summarizes information about stock options outstanding under the 2010 Share Plan as of October 31, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE
Range of Exercise Prices |  |  | Number Outstanding and Exercisable |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |
$ | 0.67 - $2.27 |  |  |  | 477,500 |  |  |  | 3.78 |  |  | $ | 1.46 |
$ | 2.58 - $3.13 |  |  |  | 515,000 |  |  |  | 2.38 |  |  | $ | 2.78 |
$ | 3.46 - $5.30 |  |  |  | 509,000 |  |  |  | 5.54 |  |  | $ | 4.17 |
ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 2018 Share Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. On the first business day of each calendar year the maximum aggregate number of shares available for future issuance is replenished such that 2,000,000 shares are available. The exercise price with respect to all of the options granted under the 2018 Share Plan was equal to the fair market value of the underlying common stock at the grant date. As of October 31, 2022, the 2018 Share Plan had 605,134 shares available for future grants. Information regarding the 2018 Share Plan for the two years ended October 31, 2022 is as follows: SCHEDULE OF OPTION ACTIVITY
|  | Shares |  |  | Weighted Average Exercise Price Per Share |  |  | Aggregate Intrinsic Value |
Options Outstanding at October 31, 2020 |  |  | 4,346,661 |  |  | $ | 3.69 |  |  |  |  |
Granted |  |  | 4,490,000 |  |  | $ | 3.82 |  |  |  |  |
Exercised |  |  | (33,888 | ) |  | $ | 3.81 |  |  |  |  |
Expired |  |  | (1,392,781 | ) |  | $ | 3.70 |  |  |  |  |
Options Outstanding at October 31, 2021 |  |  | 7,409,992 |  |  | $ | 3.76 |  |  |  |  |
Granted |  |  | 1,430,000 |  |  | $ | 2.74 |  |  |  |  |
Exercised |  |  | (22,620 | ) |  | $ | 3.15 |  |  |  |  |
Options Outstanding at October 31, 2022 |  |  | 8,817,372 |  |  | $ | 3.60 |  |  | $ | 17,644,000 |
Options Exercisable at October 31, 2022 |  |  | 5,219,039 |  |  | $ | 3.57 |  |  | $ | 10,331,000 |
The following table summarizes information about stock options outstanding under the 2018 Share Plan as of October 31, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE
|  |  | Options Outstanding |  |  | Options Exercisable |
Range of Exercise Prices |  |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |
$ | 2.09-$3.87 |  |  |  | 5,347,372 |  |  |  | 7.41 |  |  | $ | 3.24 |  |  |  | 3,927,095 |  |  |  | 6.85 |  |  | $ | 3.40 |
$ | 3.96-$5.30 |  |  |  | 3,470,000 |  |  |  | 7.98 |  |  | $ | 4.16 |  |  |  | 1,291,944 |  |  |  | 7.07 |  |  | $ | 4.09 |
Non-Plan Options In addition to options granted under stock option plans, during the years ended October 31, 2012 and 2013, the Board of Directors approved the grant of stock options to certain employees and directors (the “Non-Plan Options”). Information regarding the Non-Plan Options for the two years ended October 31, 2022 is as follows: SCHEDULE OF OPTION ACTIVITY
|  | Shares |  |  | Weighted Average Exercise Price Per Share |
Options Outstanding at October 31, 2020 |  |  | 1,698,000 |  |  | $ | 2.58 |
Exercised |  |  | (56,000 | ) |  | $ | 2.58 |
Options Outstanding October 31, 2021 |  |  | 1,642,000 |  |  | $ | 2.58 |
Exercised |  |  | (1,642,000 | ) |  | $ | 2.58 |
Options Outstanding and Exercisable at October 31, 2022 |  |  | - |  |  |  |  |
ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan which permits eligible employees to purchase shares at not less than 85% of the market value of the Company’s common stock on the offering date or the purchase date of the applicable offering period, whichever is lower. The plan was adopted by our Board of Directors on August 13, 2018 and approved by our shareholders on September 27, 2018. During the years ended October 31, 2022 and 2021, employees purchased 4,741 and 2,377 shares, respectively, with aggregate proceeds of approximately $13,000 and $6,000, respectively. Common Stock Purchase Warrants On October 30, 2020 we issued a warrant, expiring on October 30, 2025, to purchase 60,000 shares of common stock at $2.06 per share, vesting over five months, to a consultant for investor relations services. We recorded consulting expense of approximately $96,000 during the year ended October 31, 2021, based on the fair value of the warrant recognized on a straight-line basis over the vesting period. On November 16, 2021, the warrant was exercised in full on a cashless basis and 25,484 shares were withheld as payment. On November 1, 2021 we issued a warrant, expiring on October 30, 2026, to purchase 60,000 shares of common stock at $4.77 per share, vesting over five months, to a consultant for investor relations services. We recorded consulting expense of approximately $221,000 during the year ended October 31, 2022, based on the fair value of the warrant recognized on a straight-line basis over the vesting period. The warrant terminated in May 2022 upon termination of the consulting agreement. As discussed in Note 3, in connection with the March 25, 2021 public offering, we issued to certain designees of the underwriter, as compensation, warrants to purchase 300,000 shares of common stock at $6.5625 per share, expiring on March 22, 2026. Information regarding the Company’s warrants for the two years ended October 31, 2022 is as follows: SCHEDULE OF WARRANTS ACTIVITY
|  | Shares |  |  | Weighted Average Exercise Price Per Share |  |  | Aggregate Intrinsic Value |
Warrants Outstanding at October 31, 2020 |  |  | 560,000 |  |  | $ | 4.71 |  |  |  |  |
Issued |  |  | 300,000 |  |  | $ | 6.56 |  |  |  |  |
Warrants Outstanding at October 31, 2021 |  |  | 860,000 |  |  | $ | 5.36 |  |  |  |  |
Issued |  |  | 60,000 |  |  | $ | 4.77 |  |  |  |  |
Exercised |  |  | (60,000 | ) |  | $ | 2.06 |  |  |  |  |
Expired |  |  | (560,000 | ) |  | $ | 4.71 |  |  |  |  |
Warrants Outstanding and Exercisable at October 31, 2022 |  |  | 300,000 |  |  | $ | 6.56 |  |  | $ | 0 |
ANIXA BIOSCIENCES, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS The following table summarizes information about the Company’s outstanding and exercisable warrants as of October 31, 2022: SCHEDULE OF OUTSTANDING AND EXERCISABLE
Range of Exercise Prices |  |  | Number Outstanding and Exercisable |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |
$ | 6.56 |  |  |  | 300,000 |  |  |  | 3.39 |  |  | $ | 6.56 |
ZQX Advisors, LLC ZQX Advisors, LLC (“ZQX”) was an inactive joint venture in which we held a 19.5% interest, and which was dissolved during fiscal year 2021. The only assets of ZQX were shares of our common stock which were sold during fiscal year 2021, for which we received proceeds of approximately $6,000.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI https://asc.fasb.org/topic&trid=2208762 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (g) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (h) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 18 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 16 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (i) -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 50 -Paragraph 6 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration